S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
NASDAQ:CYRX

Cryoport Stock Forecast, Price & News

$63.35
-0.51 (-0.80%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$61.07
$64.00
50-Day Range
$61.78
$83.29
52-Week Range
$42.02
$86.30
Volume
592,411 shs
Average Volume
419,212 shs
Market Capitalization
$2.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.91
30 days | 90 days | 365 days | Advanced Chart
Receive CYRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Cryoport and its competitors with MarketBeat's FREE daily newsletter.


Cryoport logo

About Cryoport

CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Brentwood, TN.

Headlines

Cryoport (NASDAQ:CYRX) Trading Down 7.5%
November 17, 2021 |  americanbankingnews.com
Notable Cryoport Insider Trades $5.3M In Company Stock
November 15, 2021 |  finance.yahoo.com
Cryoport's (CYRX) "Buy" Rating Reiterated at B. Riley
November 11, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CYRX
Employees
610
Year Founded
N/A

Sales & Book Value

Annual Sales
$78.70 million
Cash Flow
$0.48 per share
Book Value
$9.54 per share

Profitability

Net Income
$-32.69 million
Pretax Margin
-11.43%

Debt

Price-To-Earnings

Miscellaneous

Free Float
41,250,000
Market Cap
$2.93 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/07/2022

MarketRank

Overall MarketRank

2.25 out of 5 stars

Transportation Sector

69th out of 172 stocks

Pharmaceutical Preparations Industry

146th out of 668 stocks

Analyst Opinion: 4.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Cryoport (NASDAQ:CYRX) Frequently Asked Questions

Is Cryoport a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cryoport in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cryoport stock.
View analyst ratings for Cryoport
or view top-rated stocks.

How has Cryoport's stock price been impacted by Coronavirus?

Cryoport's stock was trading at $16.62 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CYRX stock has increased by 281.2% and is now trading at $63.35.
View which stocks have been most impacted by COVID-19
.

When is Cryoport's next earnings date?

Cryoport is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Cryoport
.

How were Cryoport's earnings last quarter?

Cryoport, Inc. (NASDAQ:CYRX) announced its quarterly earnings results on Thursday, November, 4th. The consumer goods maker reported ($0.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.03. The consumer goods maker earned $56.69 million during the quarter, compared to the consensus estimate of $54.44 million. Cryoport had a negative net margin of 12.57% and a positive trailing twelve-month return on equity of 2.67%. The business's revenue was up 407.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.29) earnings per share.
View Cryoport's earnings history
.

What price target have analysts set for CYRX?

7 brokers have issued 12 month price objectives for Cryoport's shares. Their forecasts range from $75.00 to $95.00. On average, they anticipate Cryoport's share price to reach $87.14 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price.
View analysts' price targets for Cryoport
or view top-rated stocks among Wall Street analysts.

Who are Cryoport's key executives?

Cryoport's management team includes the following people:

What other stocks do shareholders of Cryoport own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cryoport investors own include Gilead Sciences (GILD), Advanced Micro Devices (AMD), Micron Technology (MU), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Amarin (AMRN), QUALCOMM (QCOM), Enterprise Products Partners (EPD), Pfizer (PFE) and Square (SQ).

What is Cryoport's stock symbol?

Cryoport trades on the NASDAQ under the ticker symbol "CYRX."

Who are Cryoport's major shareholders?

Cryoport's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.31%), Invesco Ltd. (5.68%), Chevy Chase Trust Holdings Inc. (4.42%), Macquarie Group Ltd. (3.13%), Victory Capital Management Inc. (2.97%) and Granite Investment Partners LLC (2.41%). Company insiders that own Cryoport stock include Daniel M Hancock, Daniel M Hancock, Edward J Zecchini, Freeze Parent LP Blackstone, Jerrell Shelton, Mark W Sawicki, Michael R Egeck, Richard J Berman and Robert Stefanovich.
View institutional ownership trends for Cryoport
.

Which institutional investors are selling Cryoport stock?

CYRX stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Lord Abbett & CO. LLC, Pier Capital LLC, BlackRock Inc., Impax Asset Management Group plc, Granahan Investment Management Inc. MA, Voya Investment Management LLC, and Granite Investment Partners LLC. Company insiders that have sold Cryoport company stock in the last year include Daniel M Hancock, Edward J Zecchini, Freeze Parent LP Blackstone, Jerrell Shelton, Mark W Sawicki, Michael R Egeck, Richard J Berman, and Robert Stefanovich.
View insider buying and selling activity for Cryoport
or view top insider-selling stocks.

Which institutional investors are buying Cryoport stock?

CYRX stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Macquarie Group Ltd., EP Wealth Advisors LLC, Point72 Asset Management L.P., Osterweis Capital Management Inc., CastleArk Alternatives LLC, Invesco Ltd., and UBS Group AG.
View insider buying and selling activity for Cryoport
or or view top insider-buying stocks.

How do I buy shares of Cryoport?

Shares of CYRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cryoport's stock price today?

One share of CYRX stock can currently be purchased for approximately $63.35.

How much money does Cryoport make?

Cryoport has a market capitalization of $2.93 billion and generates $78.70 million in revenue each year. The consumer goods maker earns $-32.69 million in net income (profit) each year or ($1.79) on an earnings per share basis.

How many employees does Cryoport have?

Cryoport employs 610 workers across the globe.

What is Cryoport's official website?

The official website for Cryoport is www.cryoport.com.

Where are Cryoport's headquarters?

How can I contact Cryoport?

Cryoport's mailing address is 112 Westwood Place Suite 350, Brentwood TN, 37027. The consumer goods maker can be reached via phone at (949) 470-2300, via email at [email protected], or via fax at 949-470-2306.


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.